Entecavir plus Fuzheng Huayu Compound Reduces the Risk of Portal Hypertension-related Complications in Patients with Compensated Hepatitis B Virus-related Cirrhosis: A Post Hoc Analysis Based on Two Randomized Controlled Trials

Fuzheng Huayu, a patent herbal product, has shown promise in liver fibrosis and cirrhosis. The effect of Fuzheng Huayu on portal hypertension due to cirrhosis and the consequent complications needs further investigation. In this study, we aimed to evaluate the association of adjunctive Fuzheng Huayu plus entecavir with liver-related events and variceal regression in patients with compensated HBV-related cirrhosis.